Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2, (Q42710837)
Jump to navigation
Jump to search
scientific article published on 26 June 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2, |
scientific article published on 26 June 2013 |
Statements
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials (English)
Thomas H Marsilje
Wei Pei
Bei Chen
Wenshuo Lu
Tetsuo Uno
Yunho Jin
Tao Jiang
Sungjoon Kim
Nanxin Li
Markus Warmuth
Yelena Sarkisova
Frank Sun
Auzon Steffy
AnneMarie C Pferdekamper
Allen G Li
Young Kim
Bo Liu
Tove Tuntland
Xiaoming Cui
Ruo Steensma
Yongqin Wan
Jiqing Jiang
Greg Chopiuk
Jie Li
W Perry Gordon
Wendy Richmond
Kevin Johnson
Jonathan Chang
Todd Groessl
You-Qun He
Andrew Phimister
Alex Aycinena
Christian C Lee
Badry Bursulaya
Donald S Karanewsky
H Martin Seidel
Jennifer L Harris
Pierre-Yves Michellys